Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Lowered to $300.00 at Scotiabank

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective dropped by investment analysts at Scotiabank from $310.00 to $300.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “sector outperform” rating on the biopharmaceutical company’s stock. Scotiabank’s price objective would indicate a potential upside of 17.39% from the company’s current price.

ALNY has been the topic of a number of other reports. HC Wainwright reiterated a “buy” rating and set a $400.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, January 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday. William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Tuesday, November 19th. Raymond James raised their price target on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. Finally, StockNews.com downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 9th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $299.43.

Alnylam Pharmaceuticals Stock Down 3.5 %

Alnylam Pharmaceuticals stock traded down $9.33 during midday trading on Friday, hitting $255.56. 322,077 shares of the stock were exchanged, compared to its average volume of 667,884. Alnylam Pharmaceuticals has a 52-week low of $141.98 and a 52-week high of $304.39. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. The business’s 50-day moving average price is $254.03 and its 200-day moving average price is $263.00. The stock has a market capitalization of $32.96 billion, a price-to-earnings ratio of -97.51 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). On average, research analysts expect that Alnylam Pharmaceuticals will post -2.24 EPS for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 5,219 shares of the stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the transaction, the chief executive officer now directly owns 78,880 shares in the company, valued at $19,797,302.40. This trade represents a 6.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CMO Pushkal Garg sold 52,592 shares of the business’s stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the sale, the chief marketing officer now owns 11,989 shares of the company’s stock, valued at approximately $3,416,865. The trade was a 81.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 73,964 shares of company stock valued at $20,622,925. Insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in ALNY. Creative Planning grew its stake in shares of Alnylam Pharmaceuticals by 24.6% during the third quarter. Creative Planning now owns 10,012 shares of the biopharmaceutical company’s stock valued at $2,754,000 after buying an additional 1,978 shares during the last quarter. Swedbank AB boosted its holdings in Alnylam Pharmaceuticals by 160.3% during the 3rd quarter. Swedbank AB now owns 53,729 shares of the biopharmaceutical company’s stock valued at $14,777,000 after acquiring an additional 33,090 shares during the period. Bleakley Financial Group LLC grew its position in Alnylam Pharmaceuticals by 24.7% during the 3rd quarter. Bleakley Financial Group LLC now owns 2,215 shares of the biopharmaceutical company’s stock worth $609,000 after acquiring an additional 439 shares during the last quarter. Blue Trust Inc. increased its stake in Alnylam Pharmaceuticals by 431.0% in the 3rd quarter. Blue Trust Inc. now owns 462 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 375 shares during the period. Finally, Friedenthal Financial bought a new stake in Alnylam Pharmaceuticals in the third quarter valued at approximately $51,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.